EP1572155A1 - Quaternary compounds comprising propolis as the active substance - Google Patents

Quaternary compounds comprising propolis as the active substance

Info

Publication number
EP1572155A1
EP1572155A1 EP03812165A EP03812165A EP1572155A1 EP 1572155 A1 EP1572155 A1 EP 1572155A1 EP 03812165 A EP03812165 A EP 03812165A EP 03812165 A EP03812165 A EP 03812165A EP 1572155 A1 EP1572155 A1 EP 1572155A1
Authority
EP
European Patent Office
Prior art keywords
compositions
active substance
propolis
substance
glycyrrhizate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03812165A
Other languages
German (de)
French (fr)
Other versions
EP1572155B1 (en
Inventor
Paolo Corvi Mora
Fabio Carli
Tiziana Canal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actimex Srl
Original Assignee
Actimex Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimex Srl filed Critical Actimex Srl
Priority to SI200330602T priority Critical patent/SI1572155T1/en
Publication of EP1572155A1 publication Critical patent/EP1572155A1/en
Application granted granted Critical
Publication of EP1572155B1 publication Critical patent/EP1572155B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A61K8/988—Honey; Royal jelly, Propolis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips

Definitions

  • the invention relates to a quaternary composition
  • a quaternary composition comprising propolis as the active substance, a delivery carrier and two co-grinding auxiliary compounds, and the use thereof as a dietary supplement or in parapharmaceutical and dermocosmetic products.
  • propolis is a special wax produced by bees which is widely used in phytotherapy as a dietary supplement, since it has no significant side effects and, on the contrary, has been shown to exert beneficial effects in various physiopathological conditions, above all in subjects with immune deficiencies due to causes of various origins.
  • antibacterial and bacteriostatic activities, antiviral and mycostatic activities, anti-inflammatory and wound healing activities are indeed attributed to propolis.
  • propolis displays a significant solubility problem and is technologically difficult to handle within the scope of perfecting suitable formulations for its dietary or parapharmaceutical uses.
  • various propolis based preparations are commercially available and mostly in the form of a dried extract or a hydroalcoholic solution.
  • the best raw material however is considered to be the dried extract which is titred in total flavonoids expressed as galangin.
  • the hydroalcoholic solution also finds extensive use, and in this case, it is also usually titred in total flavonoids, expressed as galangin.
  • the Applicant has developed a technology which is based on an original, and industrially advantageous co-grinding process of the active substances, with a hydrophilic or hydrophobic carrier and dry co-grinding auxiliary substances (Carli, F. et al. Italian patent N° MI2002A001074). With this process, ternary compositions are obtained, wherein the desired characteristics of amorphisation, solubility and dissolution speed, desired for the purposes of their specific use are conferred to the active substance selected.
  • the co-grinding mixture also comprises a co- grinding auxiliary substance, thus obtaining the desired composition in very shorter grinding times than required for known binary compositions, and under much milder operative grinding conditions.
  • hydrophilic carriers either linear or cross- linked, such as for example cyclodextrin and cyclodextrin derivatives, dextrans, polyvinylpyrrolidone, cellulose and the derivatives thereof, polyacrylic acids, manno-glucuronans, chitosans, galactomannans and sodium starch glycolate, and with linear and cross-linked hydrophobic carriers (for example ethylcellulose, polymethacrylates, polymethylmethacrylates, and polystyrene and others).
  • hydrophilic carriers either linear or cross- linked, such as for example cyclodextrin and cyclodextrin derivatives, dextrans, polyvinylpyrrolidone, cellulose and the derivatives thereof, polyacrylic acids, manno-glucuronans, chitosans, galactomannans and sodium starch glycolate
  • linear and cross-linked hydrophobic carriers for example ethylcellulose, polymethacrylates, polymethylmethacrylates, and poly
  • co-grinding auxiliary substances natural aminoacids and derivatives thereof; weak acids, such as for example malic acid, fumaric acid, ascorbic acid, citric acid; polyalcohols and derivatives; cheiating agents, such as disodium ethylenediamine tetra acetate; non ionic, anionic or cationic surfactants, as wells as lecithins, phospholipids and semisynthetic or synthetic derivatives thereof, may for example be used.
  • Amino acids, and in particular glycine, lysine, serine, and disodium ethylenediamine tetra acetate are the preferred co-grinding auxiliary substances for this ternary composition process.
  • the weight ratio between the active substance and carrier is between 1 :0.1 and 1:100 and preferably between 1:0.5 and 1:50.
  • the weight ratio between the active substance and the co-grinding auxiliary substance is between 1:0.1 and 1 :20 and preferably between 1 :0.2 and 1:10.
  • the co-grinding time is between 0.25 and 24 hours and preferably, the co- grinding time is no greater than 10 hours, and the co-grinding may be carried out using known means (ball mills, knife mills, vibrational mills, centrifugal mills and planetary mills).
  • ternary compositions comprising an active substance, a hydrophilic or hydrophobic carrier and a co-grinding auxiliary substance wherein the characteristics, such as the solubility, the dissolution speed, the solubilisation kinetics, may be altered to various extent according to the requirements of use.
  • additional advantages are represented by the catalysing effect of the co-grinding auxiliary substance, which is also effective in the hydrophilic drug / hydrophobic carrier combination and still by the fact that, being able to use lower energy levels and/or shorter grinding times, the process may also be used for substances which are poorly stable from the physico-chemical point of view, for example thermolabile substances.
  • Propolis is normally used for the most part as a dietary supplement, either in its dry extract or hydroalcoholic solution forms, however in both cases it has certain application problems, due to its poor solubility in aqueous environments, but also to its poor lipophilicity, which influences the bioavailability of the active ingredients contained therein.
  • compositions in the form of finely divided dried powders characterised by being quaternary and by comprising propolis as the active substance, a hydrophilic carrier and two co-grinding auxiliary substances, one of which is an aminoacid and the other is a sweetening agent, glycyrrhizate, have greater solubility than the corresponding ternary compositions, where the sole auxiliary substance is constituted by aminoacids.
  • the object of the present invention are said quaternary compositions, comprising propolis as the active substance, and the use thereof for the preparation of dietary supplements or parapharmaceutical and dermocosmetic products, either as such or with appropriate excipients or diluents.
  • the quaternary composition object of the invention, may have the following characteristics.
  • linear or cross-linked hydrophilic carriers such as for example cyclodextrin and cyclodextrin derivatives, and aminoacid auxiliary substances, preferentially selected from the group consisting of glycine, glutamic acid, lysine and serine are preferred.
  • the weight ratio between the active substance and the carrier may be between 1 :1 and 1 :20 and preferably between 1 :5 and 1 :8.
  • the weight ratio between the active substance and the aminoacid co-grinding auxiliary substance may between 1 :0.1 and 1 :2 and preferably between 1 :0.2 and
  • the ratio between the active substance and the second glycyrrhizate co-grinding auxiliary substance may be between 1 :0.5 and 1 :2 and preferably 1 :1.
  • the co-grinding time for the preparation of the quaternary composition is usually very short and comprised of between 0.30 and 2.0 hours.
  • Example 1 a quaternary composition with propolis, ammonium qlvcyrrhizate.
  • ⁇ cyclodextrin and L-glvcine 2 Kg of a propoflavis, ammonium glycyrrhizate, ⁇ cyclodextrin and L-glycine mixture, in the ratio of 1 :1 :7.5:0.5 w/w, are homogenised for 10 minutes in a rotating body powder mixer.
  • the mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour.
  • Example 2 a quaternary composition with propolis, ammonium qlvcyrrhizate. ⁇ cyclodextrin and qlutamic acid 2 Kg of propoflavis, ammonium glycyrrhizate, ⁇ cyclodextrin and glutamic acid mixture in a ratio of 1 :1 :7.5:0.5 w/w, are homogenised per 10 minutes in a rotating body powder mixer.
  • the mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour.
  • the product obtained, with a yield of 98.9%, is sieved and 99.8% of product recovered in the form of a finely divided free-flowing powder.
  • the quaternary compositions described may be replicated using, as the aminoacid co-grinding auxiliary substance, other aminoacids amongst which are lysine and serine.
  • ternary compositions have also been prepared without the second ammonium glycyrrhizate co-grinding auxiliary substance, in accordance with the following examples 3 and 4.
  • Example 3 a ternary composition with propolis, ⁇ cyclodextrin and L-qlvcine 1 Kg of propoflavis, ⁇ cyclodextrin and L-glycine mixture in a ratio of 1 :7.5:0.5 w/w, are homogenised for 10 minutes in a rotating body powder mixer.
  • the mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour.
  • the product obtained, with a yield of 97.8%, is sieved and 99.6% of product recovered in the form of a finely divided free-flowing powder.
  • Example 4 a ternary composition with propolis, ⁇ cyclodextrin and qlutamic acid 1 Kg of propoflavis, ⁇ cyclodextrin and glutamic acid mixture in a ratio of 1 :7.5:0.5 w/w, are homogenised for 10 minutes in a rotating body powder mixer.
  • the mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour.
  • the product obtained with a yield of 97.8%, is sieved and 99.6% of product recovered in the form of a finely divided free-flowing powder.
  • compositions of the examples 1 , 2, 3 and 4 have then been compared with the starting raw material with regard to their solubilities, obtaining the results reported in the following table 1 .
  • the ternary composition containing an aminoacid co-grinding substance causes a significant improvement in the solubility of the native propolis, but that with the addition of the second co- grinding substance - ammonium glycyrrhizate - the solubility increases further by a range comprised of between 30 and 40 % with respect to the corresponding ternary composition.
  • Such results in themselves are very significant in that it is apparent to any expert in the art that an increase in solubility, even by less than that found, may have an important and positive reflection on the bioavailability of the active ingredient(s) contained within the active substance.
  • the quaternary compositions obtained in powder form, according to the present invention may be formulated into products adapted for being used as dietary supplements or as parapharmaceutical, Including dermocosmetic, products.
  • the quaternary compositions, forming the object of the present invention may be formulated in the form of powders, even in single dose sachets, either as such or admixed with dietary or pharmaceutically acceptable excipients and diluents.
  • they may also be used in different forms, such as for example capsules, tablets, pastes, gels, solutions or suspensions and sprays, both as such and admixed with dietary or pharmaceutically acceptable excipients adapted to such other forms.
  • the quaternary compositions may be formulated cosmetic acceptable excipients as lotions, creams, ointments, pastes, gels, stick and other topical forms known for this use.
  • Vitamin E acetate 0.2 All fruit flavour 0.15
  • Example 8 chewable tablets
  • Example 10 chewable tablets
  • Example 12 chewable tablets

Abstract

The present invention describes a quaternary composition consisting of propolis delivered in a hydrophilic carrier (cyclodextrin and cyclodextrin derivatives) and co ground with the aid of two compounds for the preparation thereof in the form of a finely divided powder. The composition exhibits advantageous dissolution characteristics in aqueous environments compared to native propolis, hence resulting in greater bioavailability of the active ingredients contained therein.

Description

QUATERNARY COMPOUNDS COMPRISING PROPOLIS AS THE ACTIVE SUBSTANCE Field of the invention
The invention relates to a quaternary composition comprising propolis as the active substance, a delivery carrier and two co-grinding auxiliary compounds, and the use thereof as a dietary supplement or in parapharmaceutical and dermocosmetic products. State of the art As is known, propolis is a special wax produced by bees which is widely used in phytotherapy as a dietary supplement, since it has no significant side effects and, on the contrary, has been shown to exert beneficial effects in various physiopathological conditions, above all in subjects with immune deficiencies due to causes of various origins. In addition to immuno-stimulant activities, antibacterial and bacteriostatic activities, antiviral and mycostatic activities, anti-inflammatory and wound healing activities are indeed attributed to propolis.
From the physico-chemical point of view, it appears as a yeWow-brown resinous substance with a waxy consistency; indeed it contains resins, balsams, wax, essential oils, pollen, organic substances, mineral salts and oligoelements. Although it contains many substances peculiar to its plant origin, such as for example terpenes, polysaccharides, uronic and fatty acids, aminoacids, its many curative activities are predominantly attributed to the presence of numerous flavonoid family compounds, amongst which are chrysin, izalpin, galangin, kaempferide, pinobanksin and others, the various therapeutic effects of which have been known for some time and are undergoing a rediscovery.
In view of its nature and the substances contained therein, propolis displays a significant solubility problem and is technologically difficult to handle within the scope of perfecting suitable formulations for its dietary or parapharmaceutical uses. Indeed, various propolis based preparations are commercially available and mostly in the form of a dried extract or a hydroalcoholic solution. The best raw material however is considered to be the dried extract which is titred in total flavonoids expressed as galangin. The hydroalcoholic solution also finds extensive use, and in this case, it is also usually titred in total flavonoids, expressed as galangin.
In order to solve the problem of the administration of insoluble or poorly soluble active substances, the Applicant has developed a technology which is based on an original, and industrially advantageous co-grinding process of the active substances, with a hydrophilic or hydrophobic carrier and dry co-grinding auxiliary substances (Carli, F. et al. Italian patent N° MI2002A001074). With this process, ternary compositions are obtained, wherein the desired characteristics of amorphisation, solubility and dissolution speed, desired for the purposes of their specific use are conferred to the active substance selected. The process described in the mentioned patent is characterised in that, besides the active substance and a carrier, the co-grinding mixture also comprises a co- grinding auxiliary substance, thus obtaining the desired composition in very shorter grinding times than required for known binary compositions, and under much milder operative grinding conditions.
The process is applicable both with hydrophilic carriers, either linear or cross- linked, such as for example cyclodextrin and cyclodextrin derivatives, dextrans, polyvinylpyrrolidone, cellulose and the derivatives thereof, polyacrylic acids, manno-glucuronans, chitosans, galactomannans and sodium starch glycolate, and with linear and cross-linked hydrophobic carriers (for example ethylcellulose, polymethacrylates, polymethylmethacrylates, and polystyrene and others). As co-grinding auxiliary substances, natural aminoacids and derivatives thereof; weak acids, such as for example malic acid, fumaric acid, ascorbic acid, citric acid; polyalcohols and derivatives; cheiating agents, such as disodium ethylenediamine tetra acetate; non ionic, anionic or cationic surfactants, as wells as lecithins, phospholipids and semisynthetic or synthetic derivatives thereof, may for example be used. Amino acids, and in particular glycine, lysine, serine, and disodium ethylenediamine tetra acetate are the preferred co-grinding auxiliary substances for this ternary composition process. The weight ratio between the active substance and carrier is between 1 :0.1 and 1:100 and preferably between 1:0.5 and 1:50. The weight ratio between the active substance and the co-grinding auxiliary substance is between 1:0.1 and 1 :20 and preferably between 1 :0.2 and 1:10.
The co-grinding time is between 0.25 and 24 hours and preferably, the co- grinding time is no greater than 10 hours, and the co-grinding may be carried out using known means (ball mills, knife mills, vibrational mills, centrifugal mills and planetary mills).
The process described in the mentioned patent has various advantages, first of all the possibility of obtaining ternary compositions, comprising an active substance, a hydrophilic or hydrophobic carrier and a co-grinding auxiliary substance wherein the characteristics, such as the solubility, the dissolution speed, the solubilisation kinetics, may be altered to various extent according to the requirements of use. Furthermore, additional advantages are represented by the catalysing effect of the co-grinding auxiliary substance, which is also effective in the hydrophilic drug / hydrophobic carrier combination and still by the fact that, being able to use lower energy levels and/or shorter grinding times, the process may also be used for substances which are poorly stable from the physico-chemical point of view, for example thermolabile substances. Propolis, as already mentioned, is normally used for the most part as a dietary supplement, either in its dry extract or hydroalcoholic solution forms, however in both cases it has certain application problems, due to its poor solubility in aqueous environments, but also to its poor lipophilicity, which influences the bioavailability of the active ingredients contained therein. Summary of the invention The Applicant has now surprisingly found that compositions in the form of finely divided dried powders, characterised by being quaternary and by comprising propolis as the active substance, a hydrophilic carrier and two co-grinding auxiliary substances, one of which is an aminoacid and the other is a sweetening agent, glycyrrhizate, have greater solubility than the corresponding ternary compositions, where the sole auxiliary substance is constituted by aminoacids.
Accordingly, the object of the present invention are said quaternary compositions, comprising propolis as the active substance, and the use thereof for the preparation of dietary supplements or parapharmaceutical and dermocosmetic products, either as such or with appropriate excipients or diluents. Detailed description of the invention
The characteristics and the advantages of the composition according to the present invention will be illustrated by the following detailed description.
By using the process already mentioned previously, and described in the Italian patent N° Ml 2002A001074 for the preparation of ternary compositions, the Applicant has surprisingly found that the addition of a fourth substance, which is usually used as a sweetening agent, leads to an advantage in terms of solubility with respect to the ternary compositions which do not contain it.
Indeed, this unexpectedly behaves as a second co-grinding auxiliary substance, surprisingly improving the characteristics of the composition itself. In particular the quaternary composition, object of the invention, may have the following characteristics. For the quaternary composition comprising propolis, linear or cross-linked hydrophilic carriers, such as for example cyclodextrin and cyclodextrin derivatives, and aminoacid auxiliary substances, preferentially selected from the group consisting of glycine, glutamic acid, lysine and serine are preferred. The weight ratio between the active substance and the carrier may be between 1 :1 and 1 :20 and preferably between 1 :5 and 1 :8.
The weight ratio between the active substance and the aminoacid co-grinding auxiliary substance may between 1 :0.1 and 1 :2 and preferably between 1 :0.2 and
1 :1.
The ratio between the active substance and the second glycyrrhizate co-grinding auxiliary substance may be between 1 :0.5 and 1 :2 and preferably 1 :1.
The co-grinding time for the preparation of the quaternary composition is usually very short and comprised of between 0.30 and 2.0 hours.
The following experimental examples are given as non-exhaustive illustration of the present invention. Example 1 a quaternary composition with propolis, ammonium qlvcyrrhizate. β cyclodextrin and L-glvcine 2 Kg of a propoflavis, ammonium glycyrrhizate, β cyclodextrin and L-glycine mixture, in the ratio of 1 :1 :7.5:0.5 w/w, are homogenised for 10 minutes in a rotating body powder mixer. The mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour. The product obtained, with a yield of 98.9%, is sieved and 99.8% of the product recovered in the form of a finely divided, free-flowing powder. Example 2 a quaternary composition with propolis, ammonium qlvcyrrhizate. β cyclodextrin and qlutamic acid 2 Kg of propoflavis, ammonium glycyrrhizate, β cyclodextrin and glutamic acid mixture in a ratio of 1 :1 :7.5:0.5 w/w, are homogenised per 10 minutes in a rotating body powder mixer. The mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour. The product obtained, with a yield of 98.9%, is sieved and 99.8% of product recovered in the form of a finely divided free-flowing powder.
The quaternary compositions described may be replicated using, as the aminoacid co-grinding auxiliary substance, other aminoacids amongst which are lysine and serine.
With the aim of comparing the quaternary mixture of examples 1 and 2, ternary compositions have also been prepared without the second ammonium glycyrrhizate co-grinding auxiliary substance, in accordance with the following examples 3 and 4.
Example 3 a ternary composition with propolis, β cyclodextrin and L-qlvcine 1 Kg of propoflavis, β cyclodextrin and L-glycine mixture in a ratio of 1 :7.5:0.5 w/w, are homogenised for 10 minutes in a rotating body powder mixer. The mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour. The product obtained, with a yield of 97.8%, is sieved and 99.6% of product recovered in the form of a finely divided free-flowing powder.
Example 4 a ternary composition with propolis, β cyclodextrin and qlutamic acid 1 Kg of propoflavis, β cyclodextrin and glutamic acid mixture in a ratio of 1 :7.5:0.5 w/w, are homogenised for 10 minutes in a rotating body powder mixer. The mixture is loaded into a vibrational mill equipped with sintered alumina cylindrical milling means and subjected to grinding with a vibrational amplitude comprised of between 6 and 10 mm for 1 hour.
The product obtained, with a yield of 97.8%, is sieved and 99.6% of product recovered in the form of a finely divided free-flowing powder.
The compositions of the examples 1 , 2, 3 and 4 have then been compared with the starting raw material with regard to their solubilities, obtaining the results reported in the following table 1 .
Table 1
From the results shown above, it is clearly evident that the ternary composition containing an aminoacid co-grinding substance causes a significant improvement in the solubility of the native propolis, but that with the addition of the second co- grinding substance - ammonium glycyrrhizate - the solubility increases further by a range comprised of between 30 and 40 % with respect to the corresponding ternary composition. Such results in themselves are very significant in that it is apparent to any expert in the art that an increase in solubility, even by less than that found, may have an important and positive reflection on the bioavailability of the active ingredient(s) contained within the active substance.
The quaternary compositions obtained in powder form, according to the present invention, may be formulated into products adapted for being used as dietary supplements or as parapharmaceutical, Including dermocosmetic, products. For the uses as dietary supplements and parapharmaceutical , the quaternary compositions, forming the object of the present invention, may be formulated in the form of powders, even in single dose sachets, either as such or admixed with dietary or pharmaceutically acceptable excipients and diluents. Furthermore, they may also be used in different forms, such as for example capsules, tablets, pastes, gels, solutions or suspensions and sprays, both as such and admixed with dietary or pharmaceutically acceptable excipients adapted to such other forms.
Furthermore for the dermocosmetic use the quaternary compositions, forming the object of the present invention, may be formulated cosmetic acceptable excipients as lotions, creams, ointments, pastes, gels, stick and other topical forms known for this use.
Example 5 lip cream 2%
Components % Purified water 64.75
Vaseline oil 12.0
Dermoil HDE 5.0
Arlacel P135 3.5
Atlas G-2330 2.0 Vegetable Glycerine 3.0
Cutin HR 2.5
C-Proflavis (example 1) 2.0
Beeswax 1.1
Polyglyceryl-3 beeswax 2.0 Euxil K 300 0.8
Mg stearate 0.5
Allantoin 0.2
Karite butter 0.2
Vitamin E acetate 0.2 All fruit flavour 0.15
BHT 0.05
EDTA disodium 0.05 100
Example 6 oral cavity spray 3%
Components %
Water 92.91
C-Proflavis (example 1 ) 3.0
Menthol clathrate 1.0
Carbopol 934 0.30
30% simethicone emulsion 2.0
Sodium hydrate 18% 0.69
Methyl p-hydroxyibenzoate 0.09
Proovl p- hvdroxvibenzoate 0.01
100
Example 7 chewable tablets
Componentis mg
Biomaltodextrines 529.0
Destrates 210.0
Peppermint flavour 72.0
C-Proflavis (example 1 ) 50.0
Technological excipients 27.0
Mix biovegetable flavours 7.0
Example 8 chewable tablets
Componentis mg
Biomaltodextrines 536.0
Destrates 210.0
Apple flavour 65.0
C-Proflavis (example 1 ) 50.0
Technological excipients 27.0
Mix biovegetable flavours 7.0
Example 9 chewable tablets
Componentis mg
Biomaltodextrines 536.0
Destrates 210.0 Wood fruit flavour 65.0
C-Proflavis (example 1 ) 50.0
Technological excipients 27.0
Mix biovegetable flavours 7.0
Example 10 chewable tablets
Componentis mg
Biomaltodextrines 536.0
Destrates 210.0
Milk/honey flavour 55.0
C-Proflavis (example 1 ) 50.0
Technological excipients 27.0
Mix biovegetable flavours 17.0
Example 11 chewable tablets
Componentis mg
Biomaltodextrines 370.5
Destrates 375.5
Cola flavour 55.0
C-Proflavis (example 1 ) 50.0
Technological excipients 27.0
Mix biovegetable flavours 17.0
Example 12 chewable tablets
Componentis mg
Biomaltodextrines 506.0
Destrates 255.0
Citrus flavour 40.0
C-Proflavis (example 1 ) 50.0
Technological excipients 37.0
Mix biovegetable flavours 7.0
Example 13 effervescent tablets
Actvive principles mg
Spirea ulmaria/β cyclodextrin 100.0
C-Proflavis (example 1 ) 50.0 Rosa canina dried extract 50.0
Excipients mg
Anhydrous citric acid 2000.0
Sodium bicarbonate 600.0
Sodium carbonate 600.0
Sorbitol 340,3
E162 160,0
Orange flavour 50.0
Red orange dried extract 10% 25.0
Acesulfame K 20.0
Polisorbate 20 2.0
Dimethicone emulsion 10% 2.0
Vitamin B2 0.7

Claims

1. Compositions in the form of finely divided dried powders, characterised in that they are quaternary and comprise an active substance, propolis, a hydrophilic carrier and two co-grinding auxiliary substances, of which one is an aminoacid and one is a sweetening agent, glycyrrhizate.
2. The quaternary compositions of claim 1 wherein said compositions have a greater solubility than the corresponding ternary compositions wherein the sole auxiliary substance consists of aminoacids.
3. The compositions of claim 1 wherein the hydrophilic carrier is selected from the class of the cyclodextrins and their derivatives.
4. The compositions of claim 1 wherein the aminoacidic auxiliary substance is an aminoacid selected from the group consisting of glycine, glutamic acid, lysine and serine.
5. The compositions of claim 1 wherein the weight ratio between the active substance and the carrier is between 1 :1 and 1:20.
6. The compositions of claim 4 wherein the weight ratio between the active substance and the carrier is between 1 :5 and 1 :8.
7. The compositions of claim 1 wherein the weight ratio between the active substance and the aminoacidic auxiliary substance is between 1 :0.1 and 1:2.
8. The compositions of claim 7 wherein the weight ratio between the active substance and the aminoacidic auxiliary substance is between 1 :0.2 and 1:1.
9. The compositions of claim 1 wherein the weight ratio between the active substance and the second glycyrrhizate co-grinding auxiliary substance is of between 1:0.5 and 1 :2.
10. The compositions of claim 9 wherein the weight ratio between the active substance and the glycyrrhizate co-grinding auxiliary substance is 1:1.
11. The compositions according to one of the preceding claims wherein the weight ratios between the propolis active substance, cyclodextrin hydrophilic carrier, the aminoacidic and glycyrrhizate co-grinding auxiliary substances are 1 :7.5:0.5:1.
12. The compositions according to one or more of the preceding claims for dietary use, used either as such or in formulations with excipients and diluents suitable for dietary use in the forms selected from the group consisting of powders, capsules, tablets, pastes, gels, solutions or suspensions.
13. The compositions according to one or more of the preceding claims for parapharmaceutical use, in formulations with excipients and diluents suitable for parapharmaceutical use in the forms selected from the group consisting of powders, capsules, tablets, pastes, gels, solutions or suspensions and spray.
14. The compositions according to one or more of the preceding claims for dermocosmetic use, in formulations with excipients and diluents suitable for cosmetic use in the forms selected from the group consisting of powders, lotions, creams, ointements, pastes, gels, stick.
15. Use of the compositions in the form of finely subdivided dried powders, characterised in that they are quaternary and comprise an active substance, propolis, a hydrophilic carrier and two co-grinding auxiliary substances of which one is an aminoacid and one is a sweetening agent, glycyrrhizate, for the preparation of products in forms suitable for use as dietary supplements with or without excipients and diluents suitable for the same.
16. Use of the compositions in the form of finely divided dried powders, characterised in that they are quaternary and comprise an active substance, propolis, a hydrophilic carrier and two co-grinding auxiliary substances of which one is an aminoacid and one is a sweetening agent, glycyrrhizate, for the preparation of products in forms suitable for parapharmaceutical use with or without excipients and diluents suitable for the same.
17. Use of the compositions in the form of finely divided dried powders, characterised in that they are quaternary and comprise an active substance, propolis, a hydrophilic carrier and two co-grinding auxiliary substances of which one is an aminoacid and one is a sweetening agent, glycyrrhizate, for the preparation of products in forms suitable for dermocosmetic use with excipients and diluents suitable for the same.
18. The use of the compositions according to one or more of the preceding claims wherein said forms are powders, capsules, tablets, pastes, gels, creams, ointments, stick, solutions or suspensions, lotions and spray.
EP03812165A 2002-12-02 2003-12-02 Quaternary compounds comprising propolis as the active substance Expired - Lifetime EP1572155B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI200330602T SI1572155T1 (en) 2002-12-02 2003-12-02 Quaternary compounds comprising propolis as the active substance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002549A ITMI20022549A1 (en) 2002-12-02 2002-12-02 QUATERNARY COMPOSITION INCLUDING PROPOLIS AS AN ACTIVE SUBSTANCE.
ITMI20022549 2002-12-02
PCT/EP2003/013560 WO2004050063A1 (en) 2002-12-02 2003-12-02 Quaternary compounds comprising propolis as the active substance

Publications (2)

Publication Number Publication Date
EP1572155A1 true EP1572155A1 (en) 2005-09-14
EP1572155B1 EP1572155B1 (en) 2006-10-04

Family

ID=32448917

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03812165A Expired - Lifetime EP1572155B1 (en) 2002-12-02 2003-12-02 Quaternary compounds comprising propolis as the active substance

Country Status (12)

Country Link
US (1) US7763282B2 (en)
EP (1) EP1572155B1 (en)
JP (1) JP2006511511A (en)
CN (1) CN100398090C (en)
AT (1) ATE341307T1 (en)
AU (1) AU2003296602A1 (en)
CA (1) CA2508034A1 (en)
DE (1) DE60308899T2 (en)
ES (1) ES2274318T3 (en)
IT (1) ITMI20022549A1 (en)
RU (1) RU2005120766A (en)
WO (1) WO2004050063A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057686A1 (en) 2009-07-09 2011-05-19 Axioma Srl Oral formulations with high oral bioavailability consisting of mixtures of lipophilic and hydrophilic fractions obtained from propolis

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006025790A (en) * 2004-06-17 2006-02-02 Morikawa Kenkoudou Kk Method for solubilizing propolis into water
JP4947758B2 (en) * 2004-06-17 2012-06-06 森川健康堂株式会社 Powdered composition of propolis extract and method for producing the same
CN1311815C (en) * 2005-05-08 2007-04-25 浙江大学 Production of bee-glue microcapsule with submicron
ITPD20050224A1 (en) * 2005-07-19 2007-01-20 Actimex Srl COMPOSITIONS CONTAINING MICRONUTRIENTS IN PARTICULAR ANTIOXIDANT ACTIVITY AND THEIR USE
JP4574742B1 (en) * 2010-04-08 2010-11-04 有限会社ミールジャパン Propolis composition
JP5725832B2 (en) * 2010-12-16 2015-05-27 株式会社クラレ Chemical mechanical polishing method and slurry used therefor
CA2823995A1 (en) 2011-01-08 2012-07-12 Penny Colleen Kane Bee bloom compositions, methods of extraction and uses thereof
US20170209499A1 (en) * 2014-07-18 2017-07-27 Manuka Health New Zealand Limited Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health
GR1009068B (en) * 2016-05-09 2017-07-05 Πετρος Παναγιωτη Παναγιωτου Therapeutical spayaing healing formulation acting as a bandage for decubitus ulcers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876816A (en) * 1972-10-25 1975-04-08 Dynapol Corp Nonabsorbable, nonnutritive sweeteners
EP0109993B1 (en) * 1982-12-01 1989-02-08 Zenon M. Sosnowski Method for extracting propolis and water soluble dry propolis powder obtained thereby and cosmetic and pharmaceutical preparations containing same
JPS60188036A (en) * 1984-03-08 1985-09-25 Riken Vitamin Co Ltd Taste improvement in glycyrrhetic acid or its salt
US6005100A (en) * 1992-12-02 1999-12-21 Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo Trehalose composition for prolonging product shelf life
CN1081831A (en) * 1993-05-20 1994-02-16 李前远 A kind of health-care chewing gum and preparation method thereof
US5922324A (en) * 1995-01-31 1999-07-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Propolis extract with improved water-solubility
JPH09206003A (en) * 1996-02-06 1997-08-12 San Herusen Kk Production of propolis powder
JPH1025255A (en) * 1996-07-11 1998-01-27 Taisho Pharmaceut Co Ltd Scarcely soluble agent improved in solubility
JP2784349B2 (en) * 1996-08-26 1998-08-06 アピ株式会社 Propolis composition for food and method for producing the same
US20030104018A1 (en) * 1996-12-31 2003-06-05 Griscom Bettle Skin product having micro-spheres, and processes for the production thereof
US6248758B1 (en) * 1997-03-13 2001-06-19 Hexal Ag Pharmaceutical antacid
IT1304190B1 (en) * 1998-12-18 2001-03-08 Euphar Group Srl DEHYDROEPIANDROSTERONE CLATRATES AND RELATED PHARMACEUTICAL COMPOSITIONS
JP2000316498A (en) * 1999-04-30 2000-11-21 Piizu Communications:Kk Water-extracted propolis extract and its production
JP2001010963A (en) * 1999-06-29 2001-01-16 Api Co Ltd Propolis powder composition and its production
ITMI20021074A1 (en) * 2002-05-20 2003-11-20 Actimex S R L TERNARY COMPOSITION INCLUDING AN ACTIVE SUBSTANCE AND COMMUNICATION PROCESS FOR ITS PREPARATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004050063A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057686A1 (en) 2009-07-09 2011-05-19 Axioma Srl Oral formulations with high oral bioavailability consisting of mixtures of lipophilic and hydrophilic fractions obtained from propolis

Also Published As

Publication number Publication date
RU2005120766A (en) 2006-02-10
DE60308899T2 (en) 2007-05-10
DE60308899D1 (en) 2006-11-16
CN1720023A (en) 2006-01-11
US7763282B2 (en) 2010-07-27
US20060013891A1 (en) 2006-01-19
CN100398090C (en) 2008-07-02
AU2003296602A1 (en) 2004-06-23
CA2508034A1 (en) 2004-06-17
ITMI20022549A1 (en) 2004-06-03
WO2004050063A1 (en) 2004-06-17
ATE341307T1 (en) 2006-10-15
ES2274318T3 (en) 2007-05-16
JP2006511511A (en) 2006-04-06
EP1572155B1 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
JP5665888B2 (en) Oral care composition
US5296476A (en) Skin care compositions
CA2787965C (en) Oral care compositions
US8883225B2 (en) Water-soluble pharmaceutical compositions of hops resins
JP2001520181A (en) Compositions based on plant extracts
JPH11501918A (en) Oral composition
US7763282B2 (en) Quaternary compounds comprising propolis as the active substance
JP4104180B2 (en) Lipase activity promoter
KR101814268B1 (en) Composition with Antibacterial Effect on Oral Bacteria Containing Purified Extract of Red Ginseng Ethanol Extract
US20080138367A1 (en) Micronized vitamin c formulation
WO2000062751A2 (en) Oral care compositions containing boswellia extracts
JPH09301884A (en) Testosterone 5 alpha-reductase inhibitor containing blackberry lily extract and alpha-hydroxyl acid and its application
JP4648309B2 (en) Proanthocyanidin water-soluble conjugate and composition containing the same
JP6628839B2 (en) Astringent composition
JP6599515B2 (en) Astringent composition
JP6841222B2 (en) Saliva secretion promoter, xerostomia inhibitor and oral moisturizer, and composition
KR100613989B1 (en) Composition for oral care product including nano silk carrier
JP4222973B2 (en) Elastase activity inhibitors and cosmetics
JP2001131027A (en) Hair tonic and shampoo
US20040220151A1 (en) Process for treating tissue and suppressing pain
JP7409775B2 (en) Low astringency composition
JP2001163746A (en) Oral composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 8/73 20060101ALI20060428BHEP

Ipc: A61Q 11/00 20060101ALI20060428BHEP

Ipc: A61K 8/98 20060101AFI20060428BHEP

Ipc: A61Q 19/00 20060101ALI20060428BHEP

Ipc: A61K 8/44 20060101ALI20060428BHEP

Ipc: A61K 8/63 20060101ALI20060428BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60308899

Country of ref document: DE

Date of ref document: 20061116

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070104

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070104

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070104

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E001053

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070316

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2274318

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

26N No opposition filed

Effective date: 20070705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061202

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061004

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20090114

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081229

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20100617

Year of fee payment: 7

Ref country code: FR

Payment date: 20100623

Year of fee payment: 7

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20091202

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100624

Year of fee payment: 7

Ref country code: DE

Payment date: 20100601

Year of fee payment: 7

Ref country code: SI

Payment date: 20100531

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091203

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100531

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091202

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100531

Year of fee payment: 7

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20110616

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101202

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20110728

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101231

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110103

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101231

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60308899

Country of ref document: DE

Effective date: 20110701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101203

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110701

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20110616

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101203